KeyLights Completes Nearly RMB 100 Million Series B Funding Round Led by Luxin Venture Capital

Recently, Kelaisi (Shenzhen) Technology Co., Ltd. (hereinafter referred to as “Kelaisi”) announced the completion of its Series B financing round, raising nearly RMB 100 million. The round was led by Luxin Venture Capital Group Co., Ltd., with participation from Hanchi Venture Capital. Following this financing, Kelaisi will further accelerate the commercial promotion of its full range of in vitro diagnostic instruments, including chemiluminescence, immunofluorescence, flow fluorescence, and mass spectrometry sample preparation systems. The company aims to provide domestic and international customers with ultra-stable, high-performance, and cost-effective products and CDMO services, striving to become a leading independent brand of in vitro diagnostic instruments and a global CDMO supplier in the industry.

Kelaisi (Shenzhen) Technology Co., Ltd. was established in April 2021, and its controlled subsidiary, Chongqing Cosmoway, was founded in September 2013. As a leading domestic R&D and manufacturing enterprise for in vitro diagnostic (IVD) instruments, the company provides customized development products and services for IVD instruments, covering the entire product lifecycle including whole-machine development, core module development, design transfer, product registration, precision manufacturing, and after-sales service. Kelaisi has become a core partner for numerous listed companies and companies preparing for initial public offerings. Its products are deployed in over 800 well-known Grade III Class A hospitals, leading third-party medical laboratories, and more than 2,000 other medical institutions. Furthermore, its systems have been successfully installed and used in Germany, France, Spain, the United States, Brazil, India, Peru, Nepal, and other countries, with a cumulative global installation base exceeding 5,000 units. Kelaisi possesses an open chemiluminescence analyzer platform with fully independent intellectual property rights. Leveraging the advantages of its automated control technology platform, the company is dedicated to providing custom development of chemiluminescence instruments for diagnostic reagent manufacturers and researchers, as well as contracted R&D services for other analytical instruments such as immunofluorescence and flow fluorescence systems.

In the field of chemiluminescence immunoassay analyzers, Kelaisi has currently launched more than 10 models, including the SMART 500, SMART 6500, Venus 100, 300, 500, 6000, and 9000. The product portfolio offers various throughput options ranging from 120 T/h to 900 T/h and supports multi-unit parallel operation, thereby meeting diverse customer needs. In September 2023, the company obtained regulatory certification for its ultra-high-speed chemiluminescence analyzer, the Venus 9000, which boasts globally leading advantages in ultra-high speed and compact size, achieving a throughput of 3,600 T/h with four units linked together.

For this financing,Yu Nong, Founder and Chairman of Kelaisi, stated:

“Completing this round of financing during the confluence of industrial adjustment and a capital winter is a strong testament to our business partners’ and investors’ high recognition of Kelaisi’s strategic planning, technical capabilities, product quality, and team execution. We are committed to strengthening our technological prowess and product competitiveness amidst the growing trend of specialized collaboration in the in vitro diagnostics (IVD) industry. By continuously delivering high-quality, cost-effective products and services, we aim to enhance our partners’ operational efficiency and competitiveness, drive their commercial success, and contribute Kelaisi’s strength to the global cause of human health and well-being.”

Qiu Fang, Deputy General Manager of Luxin Venture Capital, the lead investor in this round, stated:

“As a state-controlled professional venture capital firm, Luxin Venture Capital Group Co., Ltd. has consistently adhered to supporting the domestic substitution and global expansion of mid-to-high-end medical devices through venture investment, thereby enhancing the industry competitiveness and global influence of Chinese medical device enterprises. Kelaisi (Shenzhen) Technology Co., Ltd. has accumulated ten years of expertise in the field of chemiluminescence analyzers, with a diversified product portfolio that meets customers’ varied and differentiated needs. With over 5,000 units installed to date, it has grown into a leading IVD instrument CDMO enterprise in China and an important partner within the industry. Luxin Venture Capital’s investment in Kelaisi represents a key component of its strategic layout in the life science tools sector; Luxin Venture Capital will support Kelaisi in becoming a more influential IVD instrument CDMO enterprise.”

Jin Yichen, Partner at Hanchi Venture Capital, stated:

“As a leading supplier of contract development and manufacturing (CDMO) services for in vitro diagnostic (IVD) instruments, Kelaisi offers a platform-based, diversified product portfolio that has been validated and recognized in the Chinese market, while also strengthening its overseas expansion and establishing a presence in international markets. With the continuous development of the IVD industry, increasing specialization and clearer industrial division of labor will enable Kelaisi to deliver greater value within the sector. Hanchi Venture Capital will support Kelaisi in becoming an IVD instrument CDMO provider with robust platform capabilities.”

Luxin Venture Capital Group Co., Ltd. (Stock Code: 600783.SH), controlled by Shandong Luxin Investment Holding Group Co., Ltd., is the largest professional venture capital firm in Shandong Province and one of the most influential in China. It is the first venture capital institution listed on China’s domestic capital market. Over the past two decades, the company has managed and operated more than 40 funds with a total scale of approximately RMB 20 billion, covering sectors such as healthcare, military-civilian integration, advanced manufacturing, electronic information, new energy, and new materials. Its portfolio includes over 40 companies listed both domestically and internationally. In the healthcare sector, it has invested in a number of outstanding enterprises, including 3D Medicines, Silicon-based Bionics, Zhongke New Life, Abclonal, Weimai Medical, Meidong Huicheng, Intellisense, and RemeGen.

Hanchi Venture Capital focuses on industrial investment in the healthcare sector. The fund is dedicated to investing in innovative enterprises that are technology-driven, market-oriented, and possess strong commercialization capabilities. Since its establishment in 2023, it has invested in outstanding companies such as Jinjiang Electronics, Juyi Technology, Xihua Testing, and Fengkaili Medical.